Combined treatment with BRAF and MEK inhibitors in metastatic melanomas with BRAF mutations
Rodabe N. Amaria
Immunotherapy in second-line treatment of non-small cell lung cancer
Celebrating 25 years of MASCC
ASCO 2016 melanoma highlights: immunotherapy developments and further data on checkpoint inhibitors
What's next in melanoma research on drug resistance?